ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once.







